Drugs / ARR-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07755436 | Jul 2026 → Aug 2027 expected | endometrial cancer, ovarian cancer | ArriVent BioPharma, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-11 | ArriVent BioPharma, Inc. | Regulatory ArriVent BioPharma Reports First Quarter 2026 Financial Results arrivent.com ↗
In May 2026, ArriVent received IND clearance from the FDA for ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, for ovarian and endometrial cancers. |
| 2026-05-07 | ArriVent BioPharma, Inc. | Regulatory ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers arrivent.com ↗ |
| 2026-03-17 | ArriVent BioPharma, Inc. | Results ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting arrivent.com ↗
Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-11 | ArriVent BioPharma, Inc. | ArriVent BioPharma Reports First Quarter 2026 Financial Results arrivent.com ↗ |
| 2026-05-07 | ArriVent BioPharma, Inc. | ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers arrivent.com ↗ |
| 2026-03-17 | ArriVent BioPharma, Inc. | ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting arrivent.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARR-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07755436 ↗ |